The Gujarat Kidney IPO opens for subscription on December 22 and closes on December 24, aiming to raise ₹250.80 crore through a fresh issue. Priced between ₹108 and ₹114 per share, the IPO has a grey market premium (GMP) of ₹7, indicating a modest listing gain. While the company plans aggressive expansion through hospital acquisitions and new projects, experts advise caution due to high valuation and limited short-term upside.
Gujarat Kidney IPO Day 1: Key Highlights
The initial public offering of Gujarat Kidney & Super Speciality Limited, a multispeciality healthcare services provider, opens today for investors. The IPO has attracted attention due to strong anchor investor participation and expansion-driven use of proceeds.
However, stretched valuations and execution risks have made analysts recommend a wait-and-watch approach for conservative investors.
Gujarat Kidney IPO Important Dates
| Event | Date |
|---|---|
| IPO Open Date | December 22, 2025 |
| IPO Close Date | December 24, 2025 |
| Allotment Date | December 26, 2025 |
| Refunds Initiation | December 29, 2025 |
| Shares Credit to Demat | December 29, 2025 |
| Listing Date | December 30, 2025 |
Gujarat Kidney IPO Price Band and Lot Size
| Particulars | Details |
|---|---|
| Price Band | ₹108 – ₹114 per share |
| Lot Size | 128 shares |
| Minimum Investment | ₹14,592 |
| Issue Size | ₹250.80 crore |
| Issue Type | 100% Fresh Issue |
The Gujarat Kidney IPO does not include any Offer for Sale (OFS), meaning all proceeds will go directly to the company.
Read Also: Gujarat Kidney IPO Opens on December 22: GMP, Price Band, Review, Financials and Key Risks Explained
Gujarat Kidney IPO Reservation Structure
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIBs) | Not less than 75% |
| Non-Institutional Investors (NIIs) | Up to 15% |
| Retail Individual Investors | Up to 10% |
Anchor Investors Boost Confidence
Ahead of the public issue, Gujarat Kidney raised over ₹100 crore from anchor investors by allotting 87.73 lakh shares at ₹114 per share.
Key Anchor Investors Include:
- Venus Stellar Fund
- Craft Emerging Market Fund
- Nexus Global Opportunities Fund
- Arnesta Global Fund 1
- Zeta Series C Fund
- Innovative Vision Fund
- Religo Commodities Ventures Trust
Strong anchor participation usually signals institutional confidence, although it does not guarantee post-listing performance.
Gujarat Kidney IPO GMP Today
As of December 22, the Gujarat Kidney IPO GMP stands at ₹7.
| IPO Price | GMP | Estimated Listing Price | Expected Gain |
|---|---|---|---|
| ₹114 | ₹7 | ₹121 | ~6.14% |
The grey market premium reflects moderate investor optimism but does not indicate strong listing euphoria.
How Will Gujarat Kidney Use IPO Proceeds?
The company plans to aggressively expand its healthcare footprint.
| Purpose | Amount (₹ crore) |
|---|---|
| Acquisition of Parekhs Hospital, Ahmedabad | 77.00 |
| Ashwini Medical Centre (part-payment) | 12.40 |
| Equity investment in Harmony Medicare | 10.78 |
| New Hospital Project, Vadodara | 30.09 |
| Robotics Equipment Purchase | 6.82 |
| Repayment of Borrowings | 1.20 |
| General Corporate Purposes | Remaining |
This expansion-focused strategy aligns with India’s rising demand for specialized healthcare services.
Gujarat Kidney IPO Subscription Status
The Gujarat Kidney IPO subscription status will begin updating from 10:00 AM on Day 1. Retail investors are expected to participate cautiously due to valuation concerns.
(Subscription numbers will update throughout the IPO period.)
Valuation and Financial Concerns
According to brokerage firm Swastika Investmart, the IPO is priced at around 61x P/E, which is significantly higher than many listed hospital peers.
Key Risks Highlighted:
- Aggressive valuation
- Smaller operational scale
- Integration risks from acquisitions
- Execution delays in new hospital projects
Such factors may impact earnings visibility in the short to medium term.
Should You Invest in Gujarat Kidney IPO?
Suitable For:
- Long-term investors with high risk appetite
- Investors optimistic about India’s healthcare growth story
Not Ideal For:
- Conservative investors
- Short-term listing gain seekers
Experts suggest waiting for post-listing price discovery before taking exposure, especially given the modest GMP and premium valuation.
Company Overview: Gujarat Kidney & Super Speciality
Gujarat Kidney operates in the specialized healthcare segment, focusing on nephrology, urology, and multi-speciality services. The company is expanding via acquisitions and greenfield projects to strengthen its regional presence.
FAQs on Gujarat Kidney IPO Date, GMP
Q1. What is the price band of Gujarat Kidney IPO?
The Gujarat Kidney IPO price band is ₹108 to ₹114 per share.
Q2. What is the Gujarat Kidney IPO GMP today?
The current GMP is ₹7, indicating a potential listing price of around ₹121.
Q3. Is Gujarat Kidney IPO a fresh issue?
Yes, the IPO is a 100% fresh issue with no offer for sale.
Q4. Should retail investors apply for Gujarat Kidney IPO?
Retail investors should be cautious due to high valuation and may consider waiting until post-listing.
Q5. When will Gujarat Kidney IPO list on stock exchanges?
The IPO is expected to list on December 30, 2025, on BSE and NSE.
Final Verdict
The Gujarat Kidney IPO offers exposure to a growing healthcare segment but comes with valuation concerns and execution risks. While anchor participation and expansion plans are positives, conservative investors may be better off waiting until after listing for clarity.
Join EduTaxTuber Network for the Latest News and updates on Income Tax, GST, Company Law, Stock Market and other related subjects. Learn: Microsoft Excel, MS Office, Tally Prime. Tech Learning: Python, ChatGPT
Disclaimer: The views expressed are solely those of the author and Edutaxtuber. The content in this piece is solely intended for informational purposes and for personal, non-commercial use. It should not be considered as professional advice or an endorsement by any organization. The author, the organization, and its affiliates disclaim any liability for any loss or harm resulting from the information in this article, as well as for any decisions made based on it.